Dirk Schumacher

Dirk Schumacher

Auto-generated profile, based on publicly available information

Dirk Schumacher

Charité – Universitätsmedizin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMoritz Schütte
Moritz Schütte
TRThomas Risch
Thomas Risch
NANilofar Abdavi-Azar
Nilofar Abdavi-Azar
KBKarsten Boehnke
Karsten Boehnke
DSDirk Schumacher
Dirk Schumacher
MYMarie-Laure Yaspo
Marie-Laure Yaspo
Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I–IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular sub-groups because of the loss of human stroma. Linking molecular profiles with drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.

11 June 2013 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
BKBertram Klinger
Bertram Klinger
ASAnja Sieber
Anja Sieber
RFRaphaela Fritsche
Raphaela Fritsche
FWFranziska Witzel
Franziska Witzel
LBLeanne Berry
Leanne Berry
NBNils Blüthgen
Nils Blüthgen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 October 2016 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
KBKarsten Boehnke
Karsten Boehnke
PIPhilip W. Iversen
Philip W. Iversen
DSDirk Schumacher
Dirk Schumacher
MLMaría José Lallena
María José Lallena
RHRubén Haro
Rubén Haro
JVJuan A. Velasco
Juan A. Velasco
The application of patient-derived three-dimensional culture systems as disease-specific drug sensitivity models has enormous potential to connect compound screening and clinical trials. However, the implementation of complex cell-based assay systems in drug discovery requires reliable and robust screening platforms. Here we describe the establishment of an automated platform in 384-well format for three-dimensional organoid cultures derived from colon cancer patients. Single cells were embedded in an extracellular matrix by an automated workflow and subsequently self-organized into organoid structures within 4 days of culture before being exposed to compound treatment. We performed validation of assay robustness and reproducibility via plate uniformity and replicate-experiment studies. After assay optimization, the patient-derived organoid platform passed all relevant validation criteria. In addition, we introduced a streamlined plate uniformity study to evaluate patient-derived colon cancer samples from different donors. Our results demonstrate the feasibility of using patient-derived tumor samples for high-throughput assays and their integration as disease-specific models in drug discovery.

1 December 2017 in Cell Reports
Verified
Journal Article
Open access
JRJoseph Regan
Joseph Regan
DSDirk Schumacher
Dirk Schumacher
SSStephanie Staudte
Stephanie Staudte
ASAndreas Steffen
Andreas Steffen
JHJohannes Haybaeck
Johannes Haybaeck
MLMartin Lange
Martin Lange
Colon cancer is a heterogeneous tumor driven by a subpopulation of cancer stem cells (CSCs). To study CSCs in colon cancer, we used limiting dilution spheroid and serial xenotransplantation assays to functionally define the frequency of CSCs in a panel of patient-derived cancer organoids. These studies demonstrated cancer organoids to be enriched for CSCs, which varied in frequency between tumors. Whole-transcriptome analysis identified WNT and Hedgehog signaling components to be enhanced in CSC-enriched tumors and in aldehyde dehydrogenase (ALDH)-positive CSCs. Canonical GLI-dependent Hedgehog signaling is a negative regulator of WNT signaling in normal intestine and intestinal tumors. Here, we show that Hedgehog signaling in colon CSCs is autocrine SHH-dependent, non-canonical PTCH1 dependent, and GLI independent. In addition, using small-molecule inhibitors and RNAi against SHH-palmitoylating Hedgehog acyltransferase (HHAT), we demonstrate that non-canonical Hedgehog signaling is a positive regulator of WNT signaling and required for colon CSC survival.

25 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSoulafa Mamlouk
Soulafa Mamlouk
LCLiam Harold Childs
Liam Harold Childs
DADaniela Aust
Daniela Aust
DHDaniel Heim
Daniel Heim
FMFriederike Melching
Friederike Melching
CSChristine Sers
Christine Sers
Genetic heterogeneity between and within tumours is a major factor determining cancer progression and therapy response. Here we examined DNA sequence and DNA copy-number heterogeneity in colorectal cancer (CRC) by targeted high-depth sequencing of 100 most frequently altered genes. In 97 samples, with primary tumours and matched metastases from 27 patients, we observe inter-tumour concordance for coding mutations; in contrast, gene copy numbers are highly discordant between primary tumours and metastases as validated by fluorescent in situ hybridization. To further investigate intra-tumour heterogeneity, we dissected a single tumour into 68 spatially defined samples and sequenced them separately. We identify evenly distributed coding mutations in APC and TP53 in all tumour areas, yet highly variable gene copy numbers in numerous genes. 3D morpho-molecular reconstruction reveals two clusters with divergent copy number aberrations along the proximal–distal axis indicating that DNA copy number variations are a major source of tumour heterogeneity in CRC.

29 March 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
DSDirk Schumacher
Dirk Schumacher
GAGeoffroy Andrieux
Geoffroy Andrieux
KBKarsten Boehnke
Karsten Boehnke
MKMarlen Keil
Marlen Keil
ASAlessandra Silvestri
Alessandra Silvestri
Christian RA RegenbrechtChristian RA Regenbrecht
Christian RA Regenbrecht
Organoid cultures derived from colorectal cancer (CRC) samples are increasingly used as preclinical models for studying tumor biology and the effects of targeted therapies under conditions capturing in vitro the genetic make-up of heterogeneous and even individual neoplasms. While 3D cultures are initiated from surgical specimens comprising multiple cell populations, the impact of tumor heterogeneity on drug effects in organoid cultures has not been addressed systematically. Here we have used a cohort of well-characterized CRC organoids to study the influence of tumor heterogeneity on the activity of the KRAS/MAPK-signaling pathway and the consequences of treatment by inhibitors targeting EGFR and downstream effectors. MAPK signaling, analyzed by targeted proteomics, shows unexpected heterogeneity irrespective of RAS mutations and is associated with variable responses to EGFR inhibition. In addition, we obtained evidence for intratumoral heterogeneity in drug response among parallel “sibling” 3D cultures established from a single KRAS-mutant CRC. Our results imply that separate testing of drug effects in multiple subpopulations may help to elucidate molecular correlates of tumor heterogeneity and to improve therapy response prediction in patients. Commonly occurring genetic alterations and patient-specific genetic features are increasingly used to predict the possible action of targeted cancer therapies. Although several lines of evidence have suggested that preclinical and clinical responses concur, the heterogeneity of tumors remains a severe obstacle in routinely translating preclinical data to patient treatments. Here we present a rapid work flow that integrates drug testing of three-dimensional patient tumor-derived (organoid) cultures and assessment of their genetic make-up as well as that of their donor tumors by amplicon sequencing and targeted proteomics. While the organoid cultures largely recapitulated the genomic profiles of donor tumors, the overall treatment responses and inhibitor effects on the intracellular signaling system were quite variable. Notably, organoid cultures obtained by synchronous multi-regional sampling of the same colorectal tumor showed an up to 30-fold difference in drug response. A combinatorial drug treatment improved the response. These data were confirmed in matched mouse xenograft models from the same tumor. Our findings may help to refine preclinical testing of individual tumors by modelling heterogeneity in cultures, to better understand therapeutic failure in clinical settings and to find ways to overcome treatment resistance.